Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial

• DOI: 10.1080/21645515.2021.2010428
• Publication Date: 2021-12-14T21:23:48Z
• Authors: Xiaoyu Liu; Wanqi Yang; Chao Zhang; Heng Wu; Ruize Wang; Qiang Ding; Yan Hu; Yongli Xiong; Shaobai Zhang; Lin Wang
• Keywords: Seroconversion; MMR vaccine; Measles-Mumps-Rubella Vaccine; Mumps vaccine; Japanese encephalitis vaccine; Enterovirus 71

Co-administration of vaccines could be an efficient strategy to increase vaccination uptake and reduce the number clinic visits. This randomized controlled study aimed evaluate immunogenicity safety enterovirus 71 (EV71) vaccine co-administered with measles-mumps-rubella (MMR) live-attenuated Japanese encephalitis (LA-JEV). A total 372 healthy infants were randomly assigned in a 1:1:1 ratio receive simultaneous administration EV71 (dose 1) MMR on d 0 2) LA-JEV 30 (Group 1); 30, respectively 2); or doses 1 2 3). The non-inferiority analysis seroconversion for neutralizing antibody after was primary outcome. According per protocol set, response against EV71, measles, mumps, rubella, (JE) virus similar regardless schedule. After vaccination, rate Group (107 [97.27%] 110) non-inferior that 3 (109 [97.32%] 112; difference – 0.05% [95% CI 5.38 5.21]). incidences adverse reactions 62.60% (77/123) 1, 54.84% (68/124) 2, 37.70% (46/122) 3, most them mild moderate severity. No vaccine-related serious events reported. In total, co-administration combined showed no interference demonstrated good profiles.